EUCTR2004-001988-21-HU进行中（未招募）不适用
A phase III randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate capsules [150 or 220 mg once daily starting with half dose (i.e. 75 or 110 mg) on the day of surgery] compared to subcutaneous enoxaparin 40 mg once daily for 28-35 days, in prevention of venous thromboembolism in patients with primary elective total hip replacement surgery. - RE-NOVATE (Extended thromboembolism prevention after hip surgery)
Boehringer Ingelheim Pharma Ges mbH0 个研究点目标入组 3,330 人开始时间: 2004年11月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 3,330
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients scheduled to undergo a primary, unilateral elective total hip replacement
- •2. Male or female being 18 years or older
- •3. Patients weighing at least 40 kg
- •4. Written informed consent for study participation
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. History of bleeding diathesis
- •2. Constitutional or acquired coagulation disorders that in the investigator’s judgement puts the patient at excessive risk for bleeding
- •3. Major surgery or trauma (e.g. hip fracture) within the last 3 months
- •4. Recent unstable cardiovascular disease, such as uncontrolled hypertension at the time of enrolment (investigator’s judgement) or history of myocardial infarction within the last 3 months
- •5. Spinal or epidural anaesthesia, for which more than 3 attempts at placement were made (sticks), or the placement was traumatic
- •6. Any history of haemorrhagic stroke or any of the following intracranial pathologies: bleeding, neoplasm, AV malformation or aneurysm
- •7. History of VTE still requiring specific treatment
- •8. Clinically relevant bleeding (e.g. gastrointestinal, pulmonary, intraocular or urogenital bleeding) within the last 6 months
- •9. Gastric or duodenal ulcer within the last year
- •10. Liver disease expected to have any potential impact on survival (e.g. hepatitis B or C, cirrhosis, but not Gilbert’s syndrome or hepatitis A with complete recovery)
- •11. Elevated AST or ALT > 2x upper limit of normal, based on central lab results or local lab results within 1 month before enrolment
- •12. Known severe renal insufficiency (CrCl < 30 ml/min)
- •13. Elevated creatinine, which in the investigator’s opinion contraindicates venography
- •14. Treatment with anticoagulants, clopidogrel, ticlopidine, abciximab, aspirin > 160 mg/day or NSAID with t½ > 12 hours within 7 days prior to hip replacement surgery or anticipated need during the study treatment period (COX-2 selective inihibitors are allowed)
- •15. Anticipated required use of intermittent pneumatic compression and electric stimulation of lower limb
- •16. Pre-menopausal women (last menstruation ?1 year prior to signing informed consent) who: are pregnant, nursing or are of child-bearing potential and are NOT practising acceptable methods of birth control, or do NOT plan to continue practising an acceptable method throughout the study
- •17. Known allergy to radio opaque contrast media
- •18. History of thrombocytopenia (incl. heparin induced thrombocytopenia) or a platelet count < 100,000 cells/microliter at visit 1
- •19. Allergy to heparins or dabigatran
- •20. Active malignant disease or current cytostatic treatment
- •21. Participation in a clinical trial during the last 30 days
- •22. Leg amputee
- •23. Known alcohol or drug abuse which would interfere with completion of the study
- •24. Contraindications to enoxaparin
- •25. Previous participation in this study or RE-MODEL or RE-MOBILIZE
研究者
相似试验
进行中（未招募）
不适用
A phase III randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate capsules [150 or 220 mg once daily starting with half dose (i.e. 75 or 110 mg) on the day of surgery] compared to subcutaneous enoxaparin 40 mg once daily for 28-35 days, in prevention of venous thromboembolism in patients with primary elective total hip replacement surgery. - RE-NOVATE (Extended thromboembolism prevention after hip surgery)EUCTR2004-001988-21-CZBoehringer Ingelheim Pharma Ges mbH3,330
进行中（未招募）
1 期
A phase III randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate capsules [150 or 220 mg once daily starting with half dose (i.e. 75 or 110 mg) on the day of surgery] compared to subcutaneous enoxaparin 40 mg once daily for 28-35 days, in prevention of venous thromboembolism in patients with primary elective total hip replacement surgery. - RE-NOVATE (Extended thromboembolism prevention after hip surgery)Prevention of venous thromboembolism following primary elective total hip replacement surgeryEUCTR2004-001988-21-ESBoehringer Ingelheim España, S.A.3,330
进行中（未招募）
不适用
A phase III randomised, parallel group, double-blind, active controlledstudy to investigate the efficacy and safety of oral 220 mg dabigatranetexilate (110 mg on the day of surgery followed by 220 mg once daily)compared to subcutaneous 40 mg enoxaparin once daily for 28-35 daysin prevention of venous thromboembolism in patients followingprimary elective total hip arthroplasty. (RE-NOVATE II) - RE-NOVATE IIPrimary VTE prevention in patients following total hip replacement surgeryMedDRA version: 9.1Level: LLTClassification code 10049909Term: Venous thromboembolism prophylaxisEUCTR2007-002630-11-DEBoehringer Ingelheim Pharma GmbH & Co. KG1,920
进行中（未招募）
不适用
A phase III randomised, parallel group, double-blind, active controlledstudy to investigate the efficacy and safety of oral 220 mg dabigatranetexilate (110 mg on the day of surgery followed by 220 mg once daily)compared to subcutaneous 40 mg enoxaparin once daily for 28-35 daysin prevention of venous thromboembolism in patients followingprimary elective total hip arthroplasty. (RE-NOVATE II) - RE-NOVATE IIPrimary VTE prevention in patients following total hip replacement surgeryMedDRA version: 9.1Level: LLTClassification code 10049909Term: Venous thromboembolism prophylaxisEUCTR2007-002630-11-ATBoehringer Ingelheim Pharma GesmbH1,920
进行中（未招募）
不适用
A phase III randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate capsules [150 or 220 mg once daily starting with half dose (i.e. 75 or 110 mg) on the day of surgery] compared to subcutaneous enoxaparin 40 mg once daily for 28-35 days, in prevention of venous thromboembolism in patients with primary elective total hip replacement surgery. - RE-NOVATE (Extended thromboembolism prevention after hip surgery)Prevention of venous thromboembolism following primary elective total hip replacement surgeryEUCTR2004-001988-21-DEBoehringer Ingelheim Pharma GmbH & Co. KG3,330